Description
The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizumab (Arm 2) and chemoradiation alone (Arm 1). Stratification factors include chemotherapy (cisplatin vs. carboplatin), sex (male vs. female), performance status (0/1 vs. 2), and radiation schedule (BID vs. daily).
